Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Fighting with obesity: the "gold standard" and new horizons

https://doi.org/10.20996/1819-6446-2016-12-4-450-458

Full Text:

Abstract

Data of the World Health Organization and numerous clinical studies have shown a steady increase in the prevalence of obesity in the world. The number of obese people has doubled in the last three decades. The increase in obesity prevalence with age was found in Russia in the large epidemiological study ESSE-RF. Besides, increase in obesity prevalence was observed among men. Special attention is necessary for patients with overweight or obesity in the primary prevention of chronic non-communicable diseases, such as cardiovascular disease and type 2 diabetes. Therapy aimed at addressing the risk factors of adverse outcomes is rational, if the patient has a disease associated with obesity.

About the Authors

O. M. Drapkina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


Yu. V. Dubolazova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


S. A. Boytsov
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


References

1. Ng M, Fleming T, Robinson M, Thomson B. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384(9945):766-81.

2. Jahns L, Baturin A, Popkin BM. Obesity, diet, and poverty: trends in the Russian transition to market economy. EJCN 2003;57:295-1302.

3. IASO Reanalysis of RLMS 2005 Original Source: "Russia Longitudinal Monitoring survey, RLMS-HSE", conducted by HSE and ZAO "Demoscope" together with Carolina Population Center, University of North Carolina at Chapel Hill and the Institute of Sociology RAS. Available at: http://www.cpc.unc.edu/projects/rlms-hse. Checked by Checked by 10.08.2016.

4. Balanova Iu.A., KontsevaiaA.V., Shal'nova S.A. et al. Prevalence of behavioralrisk factors for cardiovascular disease in the Russian population: Results of the ESSE-RF epidemiological study. Profilacticheskaya Meditsina 2014;5:42-52. In Russian (Баланова Ю.А., Концевая А.В., Шальнова С.А. Распространенность поведенческих факторов риска сердечнососудистых заболеваний в российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина 2014; 5: 42-52).

5. WHO. Obesity and overweight. Fact sheet N 311. Updated January 2015. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Checked by 10.08.2016.

6. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984;288:1401-4.

7. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-9.

8. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79(3):379-84.

9. Lemieux S, Prud'homme D, Bouchard C, et al. A single threshold value of waist girth identifies normalweight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64:685-93.

10. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.

11. International Diabetes Federation. The IDF consensus worldwide definition of metabolic syndrome. Brussels. 2006: 1-2. Available at: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf. Checked by 10.08.2016.

12. Simonova G.I., Mustafina S.V., Nikitin Y.P., Shcherbakova L.V. Waist circumference as indicator components of metabolic syndrome in the siberian population. Byulleten' Sibirskoy Meditsiny 2014;13(2):88-94. In Russian (Симонова Г.И., Мустафина С.В., Никитин Ю.П., Щербакова Л.В. Окружность талии как индикатор компонентов метаболического синдрома в сибирской популяции. Бюллетень Сибирской Медицины 2014;13(2):88-94).

13. National Institutes of Health. Guidelines on Overweight and Obesity: Electronic Textbook. Available at: https://www.nhlbi.nih.gov/health-pro/guidelines/current/obesity-guidelines/e_textbook/. Checked by 10.08.2016.

14. Flint AJ, Rexrode KM, Hu FB, et al. Body mass index, waist circumference, and risk of coronary heart disease: a prospective study among men and women. Obes Res Clin Pract 2010;4(3):171-81.

15. Astrup A, Cercato C, Van Gaal LF. Combating Obesity with Incretin Therapies: From Science to Clinical Practice CME. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24880830. Checked by 10.08.2016.

16. Acosta A, Abu Dayyeh BK, Port JD, Camilleri M. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 2014;63:687-95.

17. Korneeva ON, OM Drapkina The pathogenetic relationship of hypertension and insulin resistance. Rossiyskiy Kardiologicheskiy Zhurnal 2006; 5 (61): 100-3. In Russian (Корнеева О.Н., Драпкина О.М.Патогенетические взаимосвязи артериальной гипертензии и инсулинорезистентности. Российский Кардиологический Журнал 2006; 5(61): 100-3).

18. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113-32.

19. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, Ramipril, or Both in Patients atHigh Risk for Vascular Events. N Engl J Med 2008;358:1547-59.

20. Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K. ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading? Blood Pressure 2009; 18(1-2): 4-6.

21. Nedogoda S. PPAR-γ-activation – the key benefit oftelmisartan and it’s combination.Atmosfera. Novosti Kardiologii 2016; 1: 21-5. In Russian (Недогода С.В. PPAR-γ-активация – ключевое преимущество телмисартана и его комбинаций. Атмосфера. Новости Кардиологии 2016; 1: 21-5).

22. Takagi H., Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized headto-head trials. Int J Cardiol 2012; 156(1): 92-6.

23. Nedogoda S., Chumachek E.V., Tsoma V.V. et al. Losartan versus telmisartan in overweight patients with arterial hypertension. J Adv Clin Pharmacol 2015; 2(1): 1-7.

24. Neutel J.M.; the TEAMSTA Severe HTN Study Investigators. Single-Pill Combination of Telmisartan / Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. The Journal of Clinical Hypertension 2012; 14 (4):206-15.

25. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-24.

26. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. The Look AHEAD Research Group. N Engl J Med 2013; 369:145-54.

27. Cornell S., D'Souza J. Pharmacotherapy considerations in diabetes and obesity: setting patients up for success. Postgrad Med 2014;126(2):100-9.

28. Scheen AJ. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 2015;14(12):1879-904.

29. Zinman B, Wanner C, Lachin JM, et. al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes for the EMPA-REG OUTCOME Investigators. N Engl J Med 2015; 373:2117-28.

30. Ponikowski P, Voors AA, Anker SD, et. al. 2016 ESC Guidelines forthe diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016;18(8):891-975.

31. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2016;23(11):NP1-NP96.


For citation:


Drapkina O.M., Dubolazova Y.V., Boytsov S.A. Fighting with obesity: the "gold standard" and new horizons. Rational Pharmacotherapy in Cardiology. 2016;12(4):450-458. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-4-450-458

Views: 358


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)